Onglyza And The Type 2 Diabetes Approval Roadmap
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's approval of Bristol/AstraZeneca's type 2 diabetes drug sets a precedent for what kind of post-marketing work will be necessary.
You may also be interested in...
Korea's LG Life Sciences Signs Deal With China's Double-Crane Covering DPP-4 Inhibitor Gemigliptin
SEOUL - South Korea's LG Life Sciences has signed an exclusive license, supply and distribution agreement with China's Double-Crane Pharmaceutical, under which the Chinese company will sell - inside China - LG's DPP-4 inhibitor Gemigliptin for treatment of diabetes
Phenomix And Chiesi Partner For Phase III DPP-4 Drug In Europe
After the deal, Phenomix reports it has an "excellent cash position."
Phenomix And Chiesi Partner For Phase III DPP-4 Drug In Europe
After the deal, Phenomix reports it has an "excellent cash position."